PARIS, FRANCE, MONTREAL, CANADA 15 February 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), Université de Montréal and IRICoR announce that Ipsen has exercised its option to acquire exclusive rights to a pre-clinical stage program with potential oncology applications. This license agreement is the result of a fruitful collaboration established between Ipsen, Université de Montréal and IRICoR in May 2020. Ipsen […]

MONTRÉAL, January XX, 2023 – RejuvenRx Inc., an emerging biotechnology company developing novel small molecules-based targeted therapies focusing on stem cell biology, announced today a strategic investment from IRICoR, one of its co-founders.
IRICoR, a Centre of Excellence in Commercialization and Research with a focus on drug discovery, co-founded RejuvenRx alongside ExCellThera and its shareholders. This new financial investment in RejuvenRx […]

 
 
IRICoR is very pleased to announce the appointment of Gwenaëlle Gavory, as Scientific Liaison Agent. In this role, Dre Gavory will be in charge of the scientific management and progress of portfolio projects in close collaboration with the VP – Scientific operations.
Before joining IRICoR, Gwenaëlle was administrative project manager at the Institute for Research in Immunology and Cancer of the […]

With its concerted approach and its expertise in intellectual property (IP), IRICoR plays a leading role in the marketing of therapeutic solutions resulting from cutting-edge research. For the greatest benefit of patients, here and abroad.
Read the article Le Devoir (only in French)

IRICoR is very pleased to announce the appointment as of September 21, 2022 of Dr. Mario Callejo as Vice-President, Scientific Operations and new member of IRICoR’s Management team.
Dr. Callejo’s main responsibilities consist of supervising activities related to scientific affairs, such as leading and ensuring the preliminary scientific evaluation of potential projects, planning, developing and implementing a balanced portfolio strategy and making investment […]

IRICoR is therefore pleased to announce the appointment of its President and CEO, Ms. Nadine Beauger, to the Board of Directors of Canada’s Stem Cell Network (SCN).
SCN’s Board of Directors provides oversight for strategic planning, annual budgets, performance management and risk mitigation. It is also responsible for confirming the research funding recommendations of SCN’s Research Management Committee and ensuring due […]

IRICoR will participate at the LES 2022 annual meeting to be held from October 16 to 19, 2022, in San Francisco.
This event is an opportunity for intellectual property and licensing professionals to network, collaborate and discuss some of the most critical issues facing the industry today. LES 2022 annual meeting offers more than 30 sessions led by industry experts and […]

IRICoR is very pleased to announce the appointment of Nioucha Rodrigue, as a Financial Controller. In this role, Mrs Rodrigue will collaborate in the planning, development and implementation of IRICoR’s budget as well as in the forecasting process. She will also play an advisory role in optimizing the management of financial resources.
Mrs Rodrigue joins the IRICoR team with more than 10 years of […]

IRICoR is very pleased to announce the appointmentas of June 2, 2022 of Claude Larose, as Vice-President, Business Development and new member of IRICoR’s Management team. In this role, Mr. Larose will be primarily responsible for establishing links and concluding agreements with entities outside IRICoR, both in the public and private sectors, with a view to exit events for projects […]

IRICoR announces its participation in the BIO 2022 international convention to be held from June 13 to 16, 2022 in San Diego. This industry event aims to create business opportunities among life science players from all over the world. It is also an opportunity for companies and institutions to develop partnerships of interest with complementary organizations, in particular through the […]